An innovation that has kickstarted a revolution in the study and practice of health care is getting even more attention. Three scientists who pioneered the discovery and development of glucagon-like peptide-1 (GLP-1)-based obesity treatments have been named 2024 Lasker Award winners. Read More
Gastric cancer (GC) is among the most malignant tumors in terms of incidence and mortality. Early diagnosis can improve the survival rate of patients, but there is a lack of effective biomarkers for the diagnosis and prognosis of GC. Zinc finger protein 1 homologue (ZFP1) plays an important role in transcriptional regulation during embryonic development. Its homologue, MLLT10, had been found to promote carcinogenesis in leukemia and colon cancer, but limited knowledge exists on the role of ZFP1 in cancer. Read More
Argenx SE’s ARGX-119 is a monoclonal antibody (MAb) targeting the muscle-specific kinase (MuSK) Frizzled (Fz)-like domain, and has entered early clinical development for the treatment of neuromuscular diseases. Read More
Nicox SA has entered into an exclusive research and license option agreement with Glaukos Corp. for NCX-1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase PDE5 inhibitor. Read More
Investigators from Abzyme Therapeutics LLC have hypothesized that inhibiting this pathway in the CNS may prevent tissue damage and cease the progression of multiple sclerosis (MS). Read More
Zydus Lifesciences Ltd. has patented new compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors. Read More
Innate Pharma SA has obtained IND clearance from the FDA for IPH-4502, its novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) conjugated to exatecan targeting Nectin-4 in solid tumors. In nonclinical models, IPH-45 was well tolerated and showed antitumor efficacy in vitro and in vivo. Read More
A Hitgen Ltd. patent details aromatic-ring compounds acting as E3 ubiquitin-protein ligase (TRIM21) ligands reported to be useful for the treatment of cancer. Read More
Work at Innovstone Therapeutics Ltd. has led to the identification of new dihydrothienopyrimidine derivatives acting as phosphodiesterase PDE4B inhibitors. Read More
Huadong Medicine Co. Ltd. recently revealed data from in vitro and preclinical studies performed to evaluate the efficacy and pharmacokinetic, safety and tolerability profiles of a dual glucagon-like peptide 1 receptor (GLP-1R)/gastric inhibitory polypeptide receptor (GIPR) full agonist – HDM-1005. Read More
Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have jointly developed new ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) and lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase; β-glucosidase) dual inhibitors reported to be useful for the treatment of mild cognitive impairment, among others. Read More
A patent from Nagasaki University discloses new protein aggregate degradation inducers reported to be useful for the treatment of neurodegenerative diseases. Read More
Researchers from Boehringer Ingelheim Pharma GmbH & Co KG presented the discovery and preclinical characterization of new spleen tyrosine kinase (SYK) inhibitors, BI-894416 and BI-1342561, being developed for the treatment of asthma. Read More
Scientists from the Cardiovascular Research Center at the University of Virginia School of Medicine and Astrazeneca plc have developed a new mouse model of cardiovascular disease associated with genetic variations of cholesterol metabolism. The animal allows in vivo studies of myocardial infarction, plaque rupture and stroke. Read More
